Montalbán C, Obeso G, Gallego A, Castrillo J M, Bellas C, Rivas C
Department of Internal Medicine, Hospital Ramon y Cajal, Universidad de Alcalá, Spain.
Histopathology. 1993 Apr;22(4):303-10. doi: 10.1111/j.1365-2559.1993.tb00128.x.
A total of 41 non-cutaneous peripheral T-cell lymphomas were classified following the updated Kiel classification. Of these, 20 cases belonged to the low-grade group (T-cell chronic lymphocytic leukaemia, 3; lymphoepithelioid, 5; angioimmunoblastic, 4; pleomorphic small cell, 8) and 21 to the high grade group (pleomorphic medium and large cell, 11; immunoblastic, 3; large-cell anaplastic Ki-1 positive, 7). Seventy per cent showed a CD4+/CD8-phenotype, 39% a defective phenotype and 88% an activation phenotype. Eighty per cent had B-symptoms, 63% hepatomegaly, 48% splenomegaly and 26% had involvement of more than three lymphoid areas. Bone marrow was infiltrated in 34%, central nervous system in 4%, lung in 12% and skin in 14.6%. Seventeen per cent presented with extranodal disease and 82.8% had stage III/IV disease. Hypergammaglobulinaemia was found in 29%, hypercalcaemia in 7%, raised LDH serum levels in 58% and HTLV-I antibodies in only one case. Of the 37 treated patients 18 (48%) achieved a complete remission, but 33% relapsed. Mortality was 59% and actuarial overall survival at 38 months was 0.32. In the comparison of the clinical, analytical and immunophenotypic variables and outcome between low and high grade groups, only the average of bone marrow infiltration in the low grade and stage I-II, presence of defective phenotypes and higher Ki-67 positivity in the high grade group were significantly different.(ABSTRACT TRUNCATED AT 250 WORDS)
按照更新后的基尔分类法,对41例非皮肤外周T细胞淋巴瘤进行了分类。其中,20例属于低级别组(T细胞慢性淋巴细胞白血病3例;淋巴上皮样型5例;血管免疫母细胞型4例;多形性小细胞型8例),21例属于高级别组(多形性中、大细胞型11例;免疫母细胞型3例;大细胞间变性Ki-1阳性型7例)。70%表现为CD4+/CD8-表型,39%为缺陷表型,88%为活化表型。80%有B症状,63%肝肿大,48%脾肿大,26%累及三个以上淋巴区域。34%有骨髓浸润,4%有中枢神经系统浸润,12%有肺部浸润,14.6%有皮肤浸润。17%有结外病变,82.8%为Ⅲ/Ⅳ期疾病。29%有高丙种球蛋白血症,7%有高钙血症,58%乳酸脱氢酶血清水平升高,仅1例有HTLV-I抗体。在37例接受治疗的患者中,18例(48%)完全缓解,但33%复发。死亡率为59%,38个月时的精算总生存率为0.32。在比较低级别组和高级别组的临床、分析和免疫表型变量及结果时,仅低级别组Ⅰ-Ⅱ期的骨髓浸润平均值、缺陷表型的存在以及高级别组较高的Ki-67阳性率有显著差异。(摘要截选至250词)